TITLE

SUCCESSFULLY TREATED EPSTEIN-BARR VIRUS (EBY) ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH) WITH PULSE STEROID

PUB. DATE
September 2010
SOURCE
Nobel Medicus Journal;Sep-Dec2010, Vol. 6 Issue 3, p101
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
58686649

 

Related Articles

  • Hepatosplenomegaly, pancytopenia, coagulopathy: Big words about a feverish infant. Woreta, Fasika; Lockman, Justin; Heldrich, F. J.; Santosham, Mathuram; Resar, Linda M. S.; Siberry, George K. // Contemporary Pediatrics;Oct2005, Vol. 22 Issue 10, p26 

    This article presents a case study of hemophagocytic lymphohistiocytosis (HLH) in a 2-month-old boy. Hemophagocytic lymphohistiocytosis, also known as hemophagocytic syndrome, encompasses a heterogeneous group of disorders that share a nonspecific clinical picture comprising fever,...

  • Effective high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation in a patient with the aggressive form of cytophagic histiocytic panniculitis. Koizumi, K; Sawada, K; Nishio, M; Katagiri, E; Fukae, J; Fukada, Y; Tarumi, T; Notoya, A; Shimizu, T; Abe, R; Kobayashi, H; Koike, T // Bone Marrow Transplantation;7/15/97, Vol. 20 Issue 2, p171 

    A 20-year-old Japanese man developed generalized, subcutaneous, painless nodules, fever, abnormal liver function, serosal effusions, hepatosplenomegaly, lymphadenopathy and anemia. Skin biopsies revealed lobular panniculitis with a morphologically benign histiocytic infiltration and prominent...

  • Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations. Boland, I.; Vassal, G.; Morizet, J.; Terrier-Lacombe, M.-J.; Valteau-Couanet, D.; Kalifa, C.; Hartmann, O.; Gouyette, A. // British Journal of Cancer;2/15/99, Vol. 79 Issue 5/6, p787 

    High-dose busulphan-containing chemotherapy regimens have shown high response rates in children with relapsed or refractory neuroblastoma, Ewing’s sarcoma and medulloblastoma. However, the anti-tumour activity of busulfan as a single agent remains to be defined, and this was evaluated in...

  • Late relapse of acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy: report of two cases. Ferrara, Felicetto; Selleri, Carmine; Mele, Giuseppina; Serio, Bianca; Palmieri, Salvatore; Pocali, Barbara; Pane, Fabrizio; Rotoli, Bruno // Annals of Hematology;Jul2004, Vol. 83 Issue 7, p484 

    Two patients with acute promyelocytic leukemia (APL) relapsed at 111 and 84 months after achievement of complete remission (CR) induced by a combination of all-trans retinoic acid and chemotherapy. In both patients molecular remission, obtained after consolidation, had been confirmed at 60...

  • Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG). Asou, Norio; Adachi, Koichi; Tamura, Jun-ichi; Kanamaru, Akihisa; Kageyama, Shin-ichi; Hiraoka, Akira; Omoto, Eijiro; Akiyama, Hideki; Tsubaki, Kazuo; Saito, Kenji; Kuriyama, Kazutaka; Oh, Hakumei; Kitano, Kiyoshi; Miyawaki, Shuichi; Takeyama, Kunihiko; Yamada, Osamu; Nishikawa, Kiyoshi; Takahashi, Masatomo; Matsuda, Shin; Ohtake, Shigeki // Cancer Chemotherapy & Pharmacology. Supplement;Jul2001, Vol. 48, pS65 

    All-trans-retinoic acid (ATRA) has been incorporated in front-line therapy for newly diagnosed acute promyelocytic leukemia (APL). We conducted a multicenter study of differentiation therapy with ATRA alone or in combination with chemotherapy followed by intensive postremission chemotherapy in...

  • Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys. Sekeres, Mikkael A.; Schoonen, W. Marieke; Kantarjian, Hagop; List, Alan; Fryzek, Jon; Paquette, Ronald; Maciejewski, Jaroslaw P. // JNCI: Journal of the National Cancer Institute;11/5/2008, Vol. 100 Issue 21, p1542 

    Background Myelodysplastic syndromes (MDS) comprise a group of pathologically and cytogenetically distinct bone marrow disorders. Little is known about the characteristics of MDS patients, including their pathological and prognostic classifications, cytopenias, transfusion and supportive care...

  • Long-term management of thrombocytosis in essential thrombocythaemia. Birgegård, Gunnar // Annals of Hematology;Jan2009, Vol. 88 Issue 1, p1 

    Essential thrombocythaemia (ET) is an acquired myeloproliferative disorder with a prolonged clinical course and a near-normal life expectancy. Therapy is stratified according to risk of thrombohaemorrhagic events. In high-risk patients, platelet reduction is generally recommended. In...

  • A risk-benefit assessment of amifostine in cytoprotection. Mabro, M.; Faivre, S.; Raymond, E. // Drug Safety;Nov1999, Vol. 21 Issue 5, p367 

    Recent advances in chemotherapy have focused on the benefit of high dose regimens, increasing the dose intensity of conventional chemotherapy and using intensified chemotherapy with or without autologous bone marrow rescue. Dose intensity usually increases objective response rates of...

  • Various drugs.  // Reactions Weekly;6/13/2009, Issue 1256, p34 

    The article describes the case of a woman who developed severe hapatotoxicity associated with cytarabine, cefepime, amikacin, meropenem and teicoplanin. She presented with fever and was diagnosed with acute myeloid leukaemia. She was given idarubicin and cytarabine as induction chemotherapy. An...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics